SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Big Sponsors > Pfizer

QuintilesIMS leading Big Pharma firms in oncology collaboration

22-Nov-2016 - The new collaborative initiative will be led by QuintilesIMS, with founding partners including Bristol-Myers Squibb, Eli Lilly and Company, Merck KGaA, and Pfizer.

Will Pfizer renew with Icon, Parexel? Analyst says yes

17-May-2016 - This month marks the renewal period for Pfizer’s contract research organizations’ Icon and Parexel, and while revenues have been declining, analysts believe the pharma giant will renew with both companies....

Pfizer and IBM join forces to develop remote monitoring solutions

14-Apr-2016 - Using an experimental Internet of Things system that enables remote monitoring, the companies believe the multi-year project has the potential to change the way clinical trials are conducted.

Pfizer hits up four biotechs in $46m R&D collaboration strategy

19-Jan-2016 - Pfizer has invested $46m in separate collaborations with four R&D companies specialising in developing ADCs, immuno-oncology candidates and gene-therapies.

Pfizer selects Catalent to make Nexium from expanded Kentucky plant

08-Dec-2015 - Catalent will manufacture a heartburn OTC treatment for Pfizer from its newly expanded facility in Kentucky.

Pfizer-Allergan deal: what next for contract manufacturers?

25-Nov-2015 - As CMOs wait to see the short-term fallout of the Pfizer-Allergan deal, an M&A expert says contract manufacturing will follow the CRO industry in embracing strategic alliances and consolidation....

Megamerger Pfall-out? $160bn Pfizer-Allergan deal to hit CROs in short-term, analysts

24-Nov-2015 - The $160bn Pfizer-Allergan megamerger could lead to booking cancellations in the short-term say analysts, but CROs – especially Icon, Parexel and PPD - should ultimately benefit.

Roche: Small molecule exit will lead to outsourcing opportunities

16-Nov-2015 - Roche’s exit from four small molecule manufacturing plants will provide opportunities for third-party manufacturers, the firm says.

'Highest ever' cancellation rate impairs Parexel's Q1 FY16 results

02-Nov-2015 - Parexel has lowered its revenue guidance for the year following cancellations worth $305m in its first quarter FY2016.

Novartis joint venture helps virtual trial CRO to $6.5m fundraising round

26-Oct-2015 - Science 37 has raised $6.5m (€5.7m) from Lux Capital and dRx Capital, the fund set up by Novartis and Qualcomm, to advance its virtual clinical trial service business.

$47m innovation facility built in Nottingham, UK

21-Aug-2015 - The UK’s BioCity in Nottingham is adding a £30m ($47m) facility to house life science start-ups including CROs. The site will also become a hunting ground for a soon-to-launch venture...

Parexel looks to accelerate margin growth with low-cost labor

07-Aug-2015 - CRO Parexel’s staffing numbers took center stage during its earnings call Thursday as the company re-iterated plans to lay off as many as 850 employees – mostly in higher-cost countries...

Expansions of in-house R&D will have no impact on CROs, say Pfizer and Lilly

30-Jul-2015 - Despite expanding their in-house R&D facilities, both Pfizer and Eli Lilly say they remain committed to using CROs.

Icon puts up record net new business wins in Q2

29-Jul-2015 - CRO (contract research organization) Icon reported its highest level of quarterly bookings ever on Tuesday and the company’s stock jumped by about 15%. 

Research consortium looks to identify biomarkers for autism treatments

21-Jul-2015 - A new four-year research project involving a consortium of government, non-profit and other large biopharma partners is aiming to create a set of measures that can be used in clinical...

Environmental group welcomes DSM-Sinochem and GSK efforts to halt spread of antibiotic resistance

13-Jul-2015 - Antibiotic API makers have an obligation to ensure their activities do not spread resistance says a group that welcomed DSM-Sinochem’s commitment to environmentally-friendly production.

Parexel to lay off 850 amid restructuring

25-Jun-2015 - Massachusetts-based CRO Parexel is eliminating 850 positions, which it expects will cost the company $30m to $40m in employee separation benefits.

Dispatches from DIA 2015

Parexel CEO: Consolidation has created ‘ferocious’ competition among CROs

16-Jun-2015 - Competition among the top CROs, many of which are conglomerations of smaller peers, is “ferocious” right now on nearly every level, Parexel CEO Josef von Rickenbach told Outsourcing-Pharma.com at the...

FDA offers guidance for running early-phase trials for gene, cell therapies

12-Jun-2015 - As the hype continues to hover around the promise of gene and cell therapies, the latest guidance from the FDA will help sponsors, CROs and investigators design early-phase clinical trials...

Inhalable biologics: Serendex formulates with Novozymes’ Recombumin

20-May-2015 - Serendex Pharmaceutical is a step closer to developing an inhalable biopharmaceutical for lung disease after adopting stabilising tech from Novozymes.

PEOPLE ON THE MOVE

Outsourcing jobs: people on the move in pharma

13-May-2015 -

Icon CEO addresses Pfizer situation following addition of 3rd CRO partner

28-Apr-2015 - Nearly a week since Pfizer formally announced its third CRO partner as PPD , the spotlight shifted to Icon as the CRO earns nearly one-third of its revenue from Pfizer.

Dispatches from PCT US

TransCelerate CEO, leaders offer update on industry group’s activities

27-Apr-2015 - As 20 of the largest biopharma companies have now joined industry group TransCelerate, the group is beginning to use patient centricity and connectivity to influence the clinical trial environment, CEO...

Pfizer reveals PPD as third strategic CRO partner

22-Apr-2015 - Pfizer has selected PPD as its third preferred contract research organisation (CRO), but the addition will not affect ongoing relationships with Parexel and Icon, the firm says.

Dispatches from BPI 2015

Pfizer's vetting process sorts the strategic CMOs from the casual flings

15-Apr-2015 - Looking for a full-on partnership with Pfizer or a no-strings-attached manufacturing deal? Either way prepare for a tough screening process and don't be located too far from an airport.

Key Industry Events